BACKGROUND: Postsystolic shortening (PSS) may occur during myocardial ischemia. We aimed to assess the diagnostic and prognostic potential of PSS in patients with suspected stable angina pectoris (SAP). METHODS: This is a prospective study of patients with suspected SAP (N = 293), no prior cardiac history, and normal ejection fraction, who were examined by speckle-tracking echocardiography, coronary angiography, and exercise electrocardiogram. We excluded patients with known heart disease (ischemia, heart failure, valve disease), bundle branch block, pathological Q-waves, and arrhythmias. PSS was assessed using the postsystolic index (PSI), and categorical presence of PSS was defined as PSI ≥ 20% in one myocardial wall. The primary end point was major adverse cardiovascular events (MACEs), a composite of incident heart failure, myocardial infarction, and stroke. The secondary end point was MACE and revascularization (percutaneous coronary intervention/coronary artery bypass graft). RESULTS: A stenosis ≥70% in one or more coronary arteries defined significant coronary artery disease (CAD; n = 107). Patients with significant CAD had a higher prevalence of PSS (55% vs 39%; P < .002), and presence of PSS was an independent predictor of significant CAD in multivariable models adjusted for clinical data, exercise test, and echocardiographic measures (odds ratio, 2.45; 95% CI, 1.08-5.60; P = .033). The PSI confirmed this association (odds ratio, 1.71; 95% CI, 1.04-2.82; P = .034 per 1% increase). During median follow-up of 3.5 years (interquartile range, 2.7, 4.1) a total of 25 patients (8.5%) experienced MACE and 46 (15.7%) had the secondary end point. Presence of PSS was a predictor of MACE (hazard ratio, 2.57; 95% CI, 1.12-5.95; P = .028), and the association remained significant in adjusted models. Both presence of PSS and PSI were independent predictors of the secondary end point. CONCLUSIONS: In patients with suspected SAP, presence of PSS provides independent diagnostic information on significant CAD and offers novel prognostic information regarding risk of future cardiovascular events.
BACKGROUND: Postsystolic shortening (PSS) may occur during myocardial ischemia. We aimed to assess the diagnostic and prognostic potential of PSS in patients with suspected stable angina pectoris (SAP). METHODS: This is a prospective study of patients with suspected SAP (N = 293), no prior cardiac history, and normal ejection fraction, who were examined by speckle-tracking echocardiography, coronary angiography, and exercise electrocardiogram. We excluded patients with known heart disease (ischemia, heart failure, valve disease), bundle branch block, pathological Q-waves, and arrhythmias. PSS was assessed using the postsystolic index (PSI), and categorical presence of PSS was defined as PSI ≥ 20% in one myocardial wall. The primary end point was major adverse cardiovascular events (MACEs), a composite of incident heart failure, myocardial infarction, and stroke. The secondary end point was MACE and revascularization (percutaneous coronary intervention/coronary artery bypass graft). RESULTS: A stenosis ≥70% in one or more coronary arteries defined significant coronary artery disease (CAD; n = 107). Patients with significant CAD had a higher prevalence of PSS (55% vs 39%; P < .002), and presence of PSS was an independent predictor of significant CAD in multivariable models adjusted for clinical data, exercise test, and echocardiographic measures (odds ratio, 2.45; 95% CI, 1.08-5.60; P = .033). The PSI confirmed this association (odds ratio, 1.71; 95% CI, 1.04-2.82; P = .034 per 1% increase). During median follow-up of 3.5 years (interquartile range, 2.7, 4.1) a total of 25 patients (8.5%) experienced MACE and 46 (15.7%) had the secondary end point. Presence of PSS was a predictor of MACE (hazard ratio, 2.57; 95% CI, 1.12-5.95; P = .028), and the association remained significant in adjusted models. Both presence of PSS and PSI were independent predictors of the secondary end point. CONCLUSIONS: In patients with suspected SAP, presence of PSS provides independent diagnostic information on significant CAD and offers novel prognostic information regarding risk of future cardiovascular events.
Authors: Dexanda Pravian; Amiliana M Soesanto; Ade M Ambari; B R M Ario S Kuncoro; Bambang Dwiputra; Hary S Muliawan; Renan Sukmawan Journal: Int J Cardiovasc Imaging Date: 2021-05-26 Impact factor: 2.357
Authors: Philip Brainin; Sofie Reumert Biering-Sørensen; Rasmus Møgelvang; Martina Chantal de Knegt; Flemming Javier Olsen; Søren Galatius; Gunnar Hilmar Gislason; Jan Skov Jensen; Tor Biering-Sørensen Journal: Int J Cardiovasc Imaging Date: 2018-10-19 Impact factor: 2.357
Authors: Björn Östenson; Ellen Ostenfeld; Anna Werther-Evaldsson; Anders Roijer; Zoltan Bakos; Mikael Kanski; Einar Heiberg; Håkan Arheden; Rasmus Borgquist; Marcus Carlsson Journal: BMC Cardiovasc Disord Date: 2021-10-26 Impact factor: 2.298
Authors: Philip Brainin; Sune Haahr-Pedersen; Flemming Javier Olsen; Anna Engell Holm; Thomas Fritz-Hansen; Thomas Jespersen; Gunnar Gislason; Tor Biering-Sørensen Journal: J Am Heart Assoc Date: 2020-01-24 Impact factor: 5.501
Authors: Maria Concetta Pastore; Giulia Elena Mandoli; Francesco Contorni; Luna Cavigli; Marta Focardi; Flavio D'Ascenzi; Giuseppe Patti; Sergio Mondillo; Matteo Cameli Journal: Biomed Res Int Date: 2021-02-02 Impact factor: 3.411